Reduced Toxicity Matched Sibling Bone Marrow Transplant Results in Excellent Outcomes for Severe Congenital Neutropenia

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Mar 12

PMID 38469307

Authors

Joseph H Oved

Nora M Gibson

Kimberly Venella

Caitlin W Elgarten

Lisa Wray

Julia T Warren

Timothy S Olson

Affiliations

Soon will be listed here.

Abstract

Severe congenital neutropenia (SCN) is caused by germline mutations, most commonly in , impacting neutrophil maturation and leading to high risk of life-threatening infections. Most patients with mutant SCN can achieve safe neutrophil counts with chronic Granulocyte-Colony Stimulating Factor (G-CSF). However, up to 10% of patients have neutropenia refractory to G-CSF and require allogeneic stem cell transplant. Traditional conditioning for these patients includes busulfan and cyclophosphamide which is associated with significant toxicities. We present five patients with SCN without myeloid malignancy transplanted using a reduced toxicity regimen of busulfan, fludarabine and thymoglobulin. 5 pediatric patients with SCN underwent matched sibling donor bone marrow transplant (MSD-BMT) between 2014-2022 on or per CHP14BT057 (NCT02928991), a prospective, single center trial testing elimination of cyclophosphamide from conditioning in pediatric patients with single lineage inherited BMF syndromes. All patients had MSDs and no evidence of MDS. Conditioning consisted of PK-adjusted busulfan, fludarabine, and thymoglobulin, with calcineurin inhibitor and mycophenolate mofetil GVHD prophylaxis. With median follow-up of 48.4 months, overall and event-free survival were 100%. There was no acute GVHD and one instance of chronic limited GVHD. Patients exhibited >95% donor myeloid chimerism at 5 years post-BMT. Two patients experienced CMV reactivation without end-organ disease, and no other viral reactivation or significant infections occurred. MSD-BMT with reduced toxicity myeloablation for SCN provides excellent outcomes while minimizing toxicity. These data suggest that busulfan, fludarabine, and ATG can be considered an efficacious, low-toxicity standard of care regimen for patients with SCN undergoing MSD-BMT.

References

Choi S, Levine J . Indications for hematopoietic cell transplantation for children with severe congenital neutropenia. Pediatr Transplant. 2010; 14(8):937-9. DOI: 10.1111/j.1399-3046.2010.01386.x. View

Zeidler C, Welte K, Barak Y, Barriga F, Bolyard A, Boxer L . Stem cell transplantation in patients with severe congenital neutropenia without evidence of leukemic transformation. Blood. 2000; 95(4):1195-8. View

Germeshausen M, Deerberg S, Peter Y, Reimer C, Kratz C, Ballmaier M . The spectrum of ELANE mutations and their implications in severe congenital and cyclic neutropenia. Hum Mutat. 2013; 34(6):905-14. DOI: 10.1002/humu.22308. View

Olivas-Mazon R, Bueno D, Sisinni L, Mozo Y, Casado-Abad G, Perez Martinez A . A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients. Eur J Haematol. 2022; 109(5):474-482. DOI: 10.1111/ejh.13828. View

Ferry C, Ouachee M, Leblanc T, Michel G, Notz-Carrere A, Tabrizi R . Hematopoietic stem cell transplantation in severe congenital neutropenia: experience of the French SCN register. Bone Marrow Transplant. 2004; 35(1):45-50. DOI: 10.1038/sj.bmt.1704718. View

Makaryan V, Zeidler C, Bolyard A, Skokowa J, Rodger E, Kelley M . The diversity of mutations and clinical outcomes for ELANE-associated neutropenia. Curr Opin Hematol. 2014; 22(1):3-11. PMC: 4380169. DOI: 10.1097/MOH.0000000000000105. View

Donadieu J, Bellanne-Chantelot C . Genetics of severe congenital neutropenia as a gateway to personalized therapy. Hematology Am Soc Hematol Educ Program. 2022; 2022(1):658-665. PMC: 9821599. DOI: 10.1182/hematology.2022000392. View

Connelly J, Choi S, Levine J . Hematopoietic stem cell transplantation for severe congenital neutropenia. Curr Opin Hematol. 2011; 19(1):44-51. PMC: 3291495. DOI: 10.1097/MOH.0b013e32834da96e. View

Rosenberg P, Alter B, Bolyard A, Bonilla M, Boxer L, Cham B . The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. Blood. 2006; 107(12):4628-35. PMC: 1895804. DOI: 10.1182/blood-2005-11-4370. View

10.

van der Stoep M, Bertaina A, Moes D, Algeri M, Bredius R, Smiers F . Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study. Transplant Cell Ther. 2021; 28(2):99.e1-99.e7. DOI: 10.1016/j.jtct.2021.09.018. View

11.

Oshima K, Hanada R, Kobayashi R, Kato K, Nagatoshi Y, Tabuchi K . Hematopoietic stem cell transplantation in patients with severe congenital neutropenia: an analysis of 18 Japanese cases. Pediatr Transplant. 2010; 14(5):657-63. DOI: 10.1111/j.1399-3046.2010.01319.x. View

12.

Hashem H, Abu-Arja R, Auletta J, Rangarajan H, Varga E, Rose M . Successful second hematopoietic cell transplantation in severe congenital neutropenia. Pediatr Transplant. 2017; 22(1). DOI: 10.1111/petr.13078. View

13.

Carlsson G, Winiarski J, Ljungman P, Ringden O, Mattsson J, Nordenskjold M . Hematopoietic stem cell transplantation in severe congenital neutropenia. Pediatr Blood Cancer. 2010; 56(3):444-51. DOI: 10.1002/pbc.22836. View

14.

Rosenberg P, Alter B, Link D, Stein S, Rodger E, Bolyard A . Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropenia. Br J Haematol. 2007; 140(2):210-3. PMC: 3143022. DOI: 10.1111/j.1365-2141.2007.06897.x. View

15.

Horwitz M, Benson K, Person R, Aprikyan A, Dale D . Mutations in ELA2, encoding neutrophil elastase, define a 21-day biological clock in cyclic haematopoiesis. Nat Genet. 1999; 23(4):433-6. DOI: 10.1038/70544. View

16.

Ben-Barouch S, Cohen O, Vidal L, Avivi I, Ram R . Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis. Bone Marrow Transplant. 2015; 51(2):232-40. DOI: 10.1038/bmt.2015.238. View

17.

Donadieu J, Beaupain B, Mahlaoui N, Bellanne-Chantelot C . Epidemiology of congenital neutropenia. Hematol Oncol Clin North Am. 2013; 27(1):1-17, vii. DOI: 10.1016/j.hoc.2012.11.003. View

18.

Linder M, Mizoguchi Y, Hesse S, Csaba G, Tatematsu M, Lyszkiewicz M . Human genetic defects in SRP19 and SRPRA cause severe congenital neutropenia with distinctive proteome changes. Blood. 2022; 141(6):645-658. PMC: 10651786. DOI: 10.1182/blood.2022016783. View

19.

Horwitz M, Duan Z, Korkmaz B, Lee H, Mealiffe M, Salipante S . Neutrophil elastase in cyclic and severe congenital neutropenia. Blood. 2006; 109(5):1817-24. PMC: 1801070. DOI: 10.1182/blood-2006-08-019166. View

20.

Bonilla M, Gillio A, Ruggeiro M, Kernan N, Brochstein J, Abboud M . Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med. 1989; 320(24):1574-80. DOI: 10.1056/NEJM198906153202402. View